Rapid developments in the field of proteomics within recent years have enabled the reproducible and reliable quantification of large sample cohorts. Large scale studies comprising hundreds of samples are primarily processed and analyzed in one centralized facility.

Advances in mass spectrometry proteomics now make it possible to achieve unprecedented depth and coverage faster than ever before. In this case study we demonstrate the advantages of our new workflow based on the Bruker timsTOF® platform, delivering unbiased high-throughput analysis of lung cancer and healthy tissue samples in less than 24 hours.

Poster 3110/17 presented at AACR 2022

Presenter: Yuehan Feng
Session: PO.TB01.04 – Patient-Derived Xenografts
Date: April 12

The primary goal of many DIA based experiments is to discover proteins or peptides (candidates) that are differentially expressed in two or more conditions. Improvements in DIA workflow are typically measured based on identification, precision, and accuracy.

Presenter: Roland Bruderer

Date: Monday, June 5
Topic area: Biomarkers: Quantitative Analysis I

Presenter: Yuehan Feng

Date: Monday, Sep 18, 2023, 11:45 AM – 1:00 PM
Session: PP01

Presenter: Yuehan Feng

The role of the Extracellular Vesicles (EVs) proteome as a crucial indicator in melanoma progression has long been recognized, but their potential as viable clinical biomarkers has remained relatively unexplored. Moreover, most proteomic techniques are incompatible with characterizing the EVs proteome due to its wide range of protein concentrations.

In a collaborative effort with the University of Zurich, the Université de Fribourg – Universität Freiburg, and Stanford University, we have successfully devised a workflow for isolating blood-derived exosomes and profiling their proteome content using our cutting-edge TrueDiscovery® platform.

Explore the comprehensive workflow for analyzing EVs as potential biomarkers in melanoma progression in our poster.

New: Spectronaut^® 19

Unlock Your Data's True Story

New: Spectronaut^® 19

Unlock Your Data's True Story

Learn More